Key terms
About CTSO
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CTSO news
Apr 03
6:24am ET
CytoSorbents Executives Take Pay Cuts for Stock Options
Mar 14
4:49pm ET
CytoSorbents reports Q4 revenue $8.7M, consensus $9.28M
Mar 14
4:45pm ET
CytoSorbents reports FY23 EPS (64c), consensus (65c)
Mar 14
4:43pm ET
CytoSorbents reports Q4 revenue $8.7M, consensus $9.28M
Jan 17
7:19am ET
CytoSorbents reports outcomes from RCT using CytoSorb blood purification
No recent press releases are available for CTSO
CTSO Financials
Key terms
Ad Feedback
CTSO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CTSO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range